Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
ApexOnco Front Page
Recent articles
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
But could toxicity be holding back filing plans?
Syndax scored the first menin approval, but Kura is first with a licensing deal.
GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.
A CD22-directed Car that has had several owners will next year deliver its most important dataset.
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.
The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.
